ArticleAnnals of surgical oncology2026
Baseline Liver Function Predicts Long-Term Survival Beyond Perioperative Outcomes After Liver Resection for Biliary Tract Cancer.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aspartate aminotransferase-to-platelet ratio index + albumin-bilirubin (APRI+ALBI) score reflects hepatic functional reserve and is widely used for risk stratification of posthepatectomy liver failure (PHLF). However, whether baseline hepatic function also predicts long-term survival in biliary tract cancer (BTC) remains unclear. PATIENTS AND
methodsPatients undergoing curative-intent liver resection for BTC (perihilar cholangiocarcinoma [pCCA], intrahepatic cholangiocarcinoma [iCCA], gallbladder cancer [GBC]) at Mayo Clinic Rochester between 2000 and 2024 were analyzed. Patients were stratified into APRI+ALBI high and low groups using the previously published cutoff (- 2.46). To minimize baseline imbalances, 1:1 direct matching based on tumor type, age, sex, and Eastern Cooperative Oncology Group (ECOG) status was performed. OS and RFS were analyzed using Kaplan-Meier methods with log-rank testing and multivariable Cox proportional hazards regression analysis.
resultsAmong 683 eligible patients, 616 with available APRI+ALBI scores were included in the analysis. High (poor) APRI+ALBI scores were associated with male sex, pCCA, more frequent major hepatectomy and vascular resection, and higher rates of lymph node positivity and advanced tumor stage. This group also experienced increased rates of major postoperative complications, PHLF grade B/C, and 90-day mortality. Correspondingly, median OS and RFS were significantly worse in the high APRI+ALBI group (OS: 39.8 versus 62.9 months, p = 0.004; RFS: 22.2 versus 27.4 months, p = 0.019). These significant differences persisted after direct matching, and APRI+ALBI remained an independent predictor of both outcomes on multivariable Cox regression.
conclusionsPreoperative APRI+ALBI score independently predicts survival after curative-intent resection for BTC, supporting a clinically relevant link between baseline hepatic functional reserve and oncologic outcomes beyond perioperative risk.
Indexed as
Identifiers
42390669What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.